Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, Goldberg SB, Brahmer JR, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele RC, Wong KK, Heymach JV. Robichaux JP, et al. Among authors: doebele rc. Nat Med. 2024 Sep;30(9):2694-2695. doi: 10.1038/s41591-024-03178-1. Nat Med. 2024. PMID: 39164519 No abstract available.
A Rapid, Functional sgRNA Screening Method for Generating Murine RET and NTRK1 Fusion Oncogenes.
Schubert L, Le AT, Hinz TK, Navarro A, Nelson-Taylor SK, Nemenoff RA, Heasley LE, Doebele RC. Schubert L, et al. Among authors: doebele rc. bioRxiv [Preprint]. 2023 Apr 6:2023.04.06.535912. doi: 10.1101/2023.04.06.535912. bioRxiv. 2023. Update in: Biol Open. 2023 Aug 15;12(8):bio059994. doi: 10.1242/bio.059994. PMID: 37066347 Free PMC article. Updated. Preprint.
A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non-Small-Cell Lung Cancer.
Concannon KF, Glisson BS, Doebele RC, Huang C, Marotti M, Camidge DR, Heymach JV. Concannon KF, et al. Among authors: doebele rc. Clin Lung Cancer. 2024 Sep 1:S1525-7304(24)00193-1. doi: 10.1016/j.cllc.2024.08.015. Online ahead of print. Clin Lung Cancer. 2024. PMID: 39307607
Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK -driven lung cancer via concurrent integrin and MET signaling.
Hu Q, Remsing Rix LL, Desai B, Miroshnychenko D, Li X, Welsh EA, Fang B, Wright GM, Chaudhary N, Kroeger JL, Doebele RC, Koomen JM, Haura EB, Marusyk A, Rix U. Hu Q, et al. Among authors: doebele rc. bioRxiv [Preprint]. 2024 Aug 28:2024.08.27.609975. doi: 10.1101/2024.08.27.609975. bioRxiv. 2024. PMID: 39253447 Free PMC article. Preprint.
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
Blakely CM, Urisman A, Gubens MA, Mulvey CK, Allen GM, Shiboski SC, Rotow JK, Chakrabarti T, Kerr DL, Aredo JV, Bacaltos B, Gee M, Tan L, Jones KD, Devine WP, Doebele RC, Aisner DL, Patil T, Schenk EL, Bivona TG, Riess JW, Coleman M, Kratz JR, Jablons DM. Blakely CM, et al. Among authors: doebele rc. J Clin Oncol. 2024 Sep 10;42(26):3105-3114. doi: 10.1200/JCO.24.00071. Epub 2024 Jul 19. J Clin Oncol. 2024. PMID: 39028931 Free PMC article. Clinical Trial.
154 results